Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs
|First Received Date ICMJE||November 14, 2000|
|Last Updated Date||January 24, 2017|
|Start Date ICMJE||November 7, 2000|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE||Not Provided|
|Original Primary Outcome Measures ICMJE||Not Provided|
|Change History||Complete list of historical versions of study NCT00006494 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs|
|Official Title ICMJE||An Assessment of the Relationship Between Antiretroviral Drug Genotype/Phenotype (IC50) and Antiretroviral Activity in HIV-Infected, Drug-Experienced Patients With Suboptimal Suppression of Plasma Viral Load|
The purpose of this study is to determine how laboratory tests called genotyping and phenotyping assess the effectiveness of antiretroviral drugs used to treat HIV infection. Some HIV-infected patients have measurable levels of virus in their blood even though they are taking combination drug therapy-including didanosine, stavudine, or efavirenz-against HIV. Genotyping and phenotyping can be used to test for resistance to a specific drug, thereby providing information that can help doctors decide on optimal drug treatment for a given patient. Genotyping identifies mutations, or changes, the virus undergoes that allow it to continue to grow despite drug treatment. Phenotyping involves growing the virus in test tubes with different amounts of drug and then calculating how much drug is required to stop its growth.
Patients 18 years of age and older with HIV infection and viral levels between 5000 and 100,000 copies per milliliter of blood who have been taking antiretroviral therapy for at least 6 months may be eligible for this study. Candidates will be screened with a urine test and various blood tests, including genotyping and phenotyping.
Participants will have a series of tests to determine whether or not a drug is active against HIV. This involves temporarily stopping the drug under study (i.e., either efavirenz or didanosine or stavudine). The study procedure is as follows:
|Detailed Description||The efficacy of highly active antiretroviral therapy (HAART) is limited by the emergence of drug-resistant virus strains. Development of resistance to one or more antiretroviral drugs in a HAART regimen may result in substantial rebound viremia and require a new drug regimen. The use of virus genotyping or phenotyping to identify drugs likely to be active in an anti-retroviral experienced patient is now recommended, but these tests have limitations and their clinical utility has not yet been established. The goal of this project is to investigate the correlation between phenotype/genotype to selected antiretroviral agents and short-term change in viral load upon discontinuation of a single antiretroviral agent from a failing regimen. For the nucleoside reverse transcriptase inhibitors (NRTIs) and the protease inhibitors, resistance is poorly understood; thus, we plan to determine whether a change in viral load occurs after discontinuing these drugs. If so, we plan to correlate those changes with phenotypic and genotypic characteristics. Study participants must have a stable viral load of at least 1000 copies/ml by bDNA assay despite HAART and must be receiving one of the anti-retroviral agents designated for study:. Baseline viral load will be established by multiple bDNA sampling over a 10-day period. Next, the drug of interest will be withdrawn and the rest of the regimen maintained for either a two week (NRTIs except 3TC, protease inhibitor) or four week (3TC) discontinuation to assess for change in viral load. Finally, the withdrawn agent will be re-instituted, and serial sampling for change in viral load, genotype or phenotype will follow.|
|Study Type ICMJE||Observational|
|Study Design ICMJE||Not Provided|
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Not Provided|
|Study Population||Not Provided|
|Condition ICMJE||HIV Infection|
|Intervention ICMJE||Not Provided|
|Study Groups/Cohorts||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Estimated Completion Date||September 6, 2011|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
In order to enroll, subjects must:
Be HIV infected.
Be currently receiving highly active anti-retroviral therapy. Drugs available through expanded access or compassionate use protocols are permitted.
Have received at least 6 months of HAART therapy.
Currently be receiving and be willing to temporarily discontinue the selected antiretroviral for the indicated duration.
Have a viral load between 1,000 and 100,000 copies/ml within 6 weeks prior to screen or at screening.
If one value is greater than 100,000 copies and one value less, the average of the two viral loads will be used to determine eligibility. Similarly, if one value is less than 1,000 and one value greater than 1,000, the average viral load will be used to determine eligibility.
Have two viral load tests by bDNA method in the NIH laboratory that differ by less than 20% (log10bDNA) in the three weeks prior to enrollment. Viral loads performed through participation in another NIAID study are acceptable. Alternatively, new patients coming to the clinic are permitted to have two screening visits.
Have a CD4 T cell number greater than 100 cells within 4 weeks of enrollment or greater than 100 cells within 8 weeks of enrollment if no more recent CD4 cell count is available.
Be adults age 18 or older.
Self-report adequate adherence to antiviral medications (missing at most one dose of drug weekly) and commit to work towards adherence during study participation.
In order to enroll, subjects must not:
Have a positive pregnancy test.
Have evidence of recent HIV infection, defined as a history of a negative HIV ELISA within 12 months of screening.
Have any acute infection that might alter viral load with the previous 4 weeks.
Have received a vaccine in the previous 4 weeks.
Have symptomatic HIV disease for which rapid institution of a salvage regimen would be advisable.
Be receiving concomitant medications or have a concomitant illness with malabsorption or emesis that could be expected to result in inadequate concentrations of antiretroviral drugs.
Be receiving an anti-retroviral regimen that includes drugs that should not be used concomitantly (e.g., stavudine and zidovudine) or inadvisable dosages of antiretroviral agents.
Have any laboratory abnormality for which withdrawal of a drug or drug regimen might be considered. For the purposes of general guidance, Grade III toxicities would result in exclusion from study with the exception of stable thrombocytopenia or proteinuria or elevated bilirubin resulting from Gilbert's syndrome or indinavir treatment. Grade II SGOT or SGPT might be a reason for study exclusion if not explained by underlying hepatitis or if in a pattern of recent increase over a stable baseline.
Have genotypic evidence at screening that would suggest that discontinuing the selected antiretroviral would result in suboptimal therapy that would clearly place the remainder of the regimen at risk for the development of new resistance mutations during the discontinuation period. Two prominent possibilities would be patients taking NNRTI regimens and discontinuing NRTIs or PI component in patients who have genotypes with no NNRTI mutations. During the discontinuation period, it would be possible that the patient may acquire new resistance mutations to NNRTIs. Genotype may be performed as part of the screen or be performed through PMD.
Have had a change in antiretroviral regimen in the past 6 weeks.
Have received cytotoxic chemotherapy including hydroxyurea in the last 6 weeks, or have anticipated need for chemotherapy during study.
Have evidence of active hepatitis B infection and wish to interrupt either tenofovir or 3TC.
Have any suggestion of a trend to increase or decrease in viral load in the past 6 weeks.
Have significant active substance abuse or psychiatric illness that might interfere with study assessments or with your ability to return for study visits.
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT00006494|
|Other Study ID Numbers ICMJE||010004, 01-I-0004|
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Not Provided|
|Study Sponsor ICMJE||National Institute of Allergy and Infectious Diseases (NIAID)|
|Collaborators ICMJE||Not Provided|
|Investigators ICMJE||Not Provided|
|Information Provided By||National Institutes of Health Clinical Center (CC)|
|Verification Date||September 6, 2011|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP